Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience Abstract #157

Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.
Aim(s): To present our experience with MEN 1 patients, including clinical and genetic information.
Materials and methods: Clinical data was obtained for patients followed at Hadassah Medical Center between the years 2003-2009. Genetic analysis was carried out in the laboratory of Prof. A Calender, France, and the NIH, USA, and included direct sequencing and quantitative multiplex short fragment PCR of exons 2-10 of the menin gene. Clinical diagnosis of MEN 1 was defined as the presence of at least two out of the three main manifestations of MEN 1 (PT, GEP, pituitary).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem

To read results and conclusion, please login ...

Further abstracts you may be interested in

#524 Sunitinib in a MEN-1 Patient with Small Cell Neuroendocrine Tumor of the Thymus
Introduction: MEN-1 is an autosomal dominant disease caused by mutation of the oncosuppressor gene menin. MEN-1 is typically associated with hyperparathyroidism, islet cell tumors and pituitary adenomas, but it can also be associated with other neoplasms, such as thymic carcinoids.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Prof Giovannella Palmieri
#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience
Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Merav Fraenkel
#348 Management of Multiple Endocrine Neoplasia Type 1 in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Screening for MEN-1 is an integral part of examination of patients with pNETs because revelation of this hereditary pathology radically influences tactics of treatment.
Conference:
Category: Basic
Presenting Author: Ivan Vasiliev
#1722 New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome associated with an increased risk of developing parathyroid, pituitary and pancreatic neuroendocrine tumors. MEN1 has an autosomal dominant pattern of hereditability and it is usually related to mutations in menin coding gene
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola